You are here

Article Text

Article menu
Download PDFPDF
Scientific correspondence
Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis
  1. Mark D Daniell1001,
  2. John K G Dart1002,
  3. Susan Lightman1002,1003
  1. 1001Corneal Service, Royal Victorian Eye and Ear Hospital, Melbourne, Australia, 1002Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK, 1003Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK
  1. John K G Dartjdart{at}dial.pipex.com

Abstract

AIMS To demonstrate that oral cyclosporin is successful in the management of steroid refractory post-keratoplasty atopic sclerokeratitis (PKAS).

METHODS Series of three patients.

RESULTS The patients developed PKAS between 2 and 11 days after surgery. All cases failed to respond to oral prednisolone 60–80 mg daily for 10–30 days but resolved with the addition of systemic cyclosporin 5.0–7.5 mg/kg/day. There have been no relapses following withdrawal of therapy after 3–18 months.

CONCLUSIONS PKAS is an uncommon, but severe, complication of corneal graft surgery and often responds to oral prednisolone treatment. Oral cyclosporin results in rapid resolution of PKAS in steroid unresponsive cases.

  • keratoconus
  • atopy
  • post-keratoplasty atopic sclerokeratitis
  • immunosuppression
  • cyclosporin

https://doi.org/10.1136/bjo.85.1.91

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes